Galsulfase (Drug Plan Submission)

Details

Files

Generic Name:

Project Status:

Complete

Therapeutic Area:

Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome)

Manufacturer:

BioMarin Pharmaceutical (Canada) Inc.

Call for patient/clinician input open:

April 27, 2015

Brand Name:

Naglazyme

Project Line:

Reimbursement Review

Project Number:

SR0434-000

Call for patient/clinician input closed:

June 16, 2015

NOC Status at Filing:

Post NOC

Performance Metric:

Achieved

Submission Type:

Drug Plan Initiated

Indications:

Mucopolysaccharidosis VI

Recommendation Type:

List with clinical criteria and/or conditions

Final Recommendation:

February 19, 2016

Last Updated : April 27, 2015